# A Study to Assess the Ability of a Novel Endocrine Treatment for Breast Cancer, Irosustat, to Slow Down Cancer Growth

> **NCT01662726** · PHASE2 · TERMINATED · sponsor: **Imperial College London** · enrollment: 13 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Irosustat

## Key facts

- **NCT ID:** NCT01662726
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-08
- **Primary completion:** 2014-07
- **Final completion:** 2014-12
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Recruitment challenging: lack of suitable pts; recruiting so soon after diagnosis; competing studies. Funding ended despite extensions to grant.
- **Last updated:** 2016-03-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01662726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01662726, "A Study to Assess the Ability of a Novel Endocrine Treatment for Breast Cancer, Irosustat, to Slow Down Cancer Growth". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01662726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*